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Strengths and limitations of this study
 ► This study is a large individually randomised place-
bo-controlled trial evaluating a single dose of azith-
romycin compared with a single dose of matching 
placebo during the neonatal period for the preven-
tion of infant mortality.
 ► This study will use an identical matching placebo, 
which will minimise bias between the two arms, and 
participants, outcome assessors and investigators 
are masked to treatment allocation.
 ► Infants will be carefully monitored for adverse 
events following treatment administration to screen 
for infantile hypertrophic pyloric stenosis (IHPS) and 
other potential adverse events.
 ► Limitations of this study include the limited num-
ber of assessments that can be made with a large 
sample size and that the study may be underpow-
ered to detect IHPS, given the expected rarity of the 
condition.
ABSTRACT
Introduction Biannual mass azithromycin distribution to 
children aged 1–59 months has been shown to reduce 
all-cause mortality. Children under 28 days of age were 
not treated in studies evaluating mass azithromycin 
distribution for child mortality due to concerns related 
to infantile hypertrophic pyloric stenosis (IHPS). Here, 
we report the design of a randomised controlled trial 
to evaluate the efficacy and safety of administration of 
a single dose of oral azithromycin during the neonatal 
period.
Methods and analysis The Nouveaux-nés et 
Azithromycine: une Innovation dans le Traitement des 
Enfants (NAITRE) study is a double-masked randomised 
placebo-controlled trial designed to evaluate the efficacy 
of a single dose of azithromycin (20 mg/kg) for the 
prevention of child mortality. Newborns (n=21 712) aged 
8–27 days weighing at least 2500 g are 1:1 randomised 
to a single, directly observed, oral dose of azithromycin 
or matching placebo. Participants are followed weekly 
for 3 weeks after treatment to screen for adverse events, 
including IHPS. The primary outcome is all-cause mortality 
at the 6-month study visit.
Ethics and dissemination This study was approved 
by the Institutional Review Boards at the University of 
California, San Francisco in San Francisco, USA (Protocol 
#18-25027) and the Comité National d’Ethique pour 
la Recherche in Ouagadougou, Burkina Faso (Protocol 
#2018-10-123). The findings of this trial will be presented 
at local, regional and international meetings and published 
in open access peer-reviewed journals.
Trial registration number NCT03682653; Pre-results.
InTRoduCTIon
The MORDOR study demonstrated that mass 
azithromycin distribution reduces all-cause 
child mortality relative to placebo in high 
mortality settings in sub-Saharan Africa.1 2 The 
largest effects were seen in the youngest chil-
dren, with nearly 25% reduction in mortality 
in children aged 1–5 months. Children in this 
age range have the highest risk of mortality 
and thus may have the most to gain from child 
survival interventions. MORDOR treated 
children as young as 1 month of age due to 
increased mortality in this population but did 
not treat children before 28 days of life due 
to concerns related to potentially increased 
risk of infantile hypertrophic pyloric stenosis 
(IHPS) related to macrolide use.3 4 No cases 
of IHPS or increases in vomiting were found 
in infants aged 1–5 months receiving azithro-
mycin in MORDOR relative to placebo.5
Globally, reductions in neonatal mortality 
have been slower than reduction in post-neo-
natal mortality, and slow progress in reduction 
in neonatal mortality has affected overall prog-
ress in achieving under-five mortality targets.6 7 
The majority of neonatal deaths occur during 
the first week of life, a majority of which are 
due to preterm birth and intrapartum-re-
lated conditions.7 8 Neonatal mortality is more 
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Figure 1 Study flow diagram for study visits and outcome assessments.
likely to be infectious in nature in the late neonatal period 
(8–27 days), during which time the most common cause of 
neonatal mortality is sepsis.7 Post-neonatal infant mortality 
(mortality in children aged 28 to 364 days) is higher than in 
older children, and in sub-Saharan Africa mortality in this 
age group is largely infectious in nature.9 Any effect of azith-
romycin for prevention of child mortality is likely achieved 
through reductions in infectious mortality.10 Distribution of 
azithromycin during early infancy when the risk of infec-
tious mortality is highest may prove to be an efficacious 
strategy for targeting azithromycin treatment for child 
survival. Here, we describe an individually randomised 
placebo-controlled double-masked trial designed to estab-
lish the efficacy of administration of azithromycin during 
the neonatal period for the prevention of child mortality. 
Our central hypothesis is that a single oral dose of azithro-
mycin administered during the neonatal period will reduce 
all-cause infant mortality compared with a single dose of 
placebo.
METhodS/dESIgn
Study design
The Nouveaux-nés et Azithromycine: une Innovation dans le 
Traitement des Enfants (NAITRE) study is an individually 
randomised placebo-controlled trial designed to evaluate 
the efficacy and safety of administration of a single dose 
of oral azithromycin during the neonatal period for the 
prevention of infant mortality (figure 1). Neonates aged 
8–27 days are randomised in a 1:1 fashion to a single dose 
of oral azithromycin or matching placebo and followed for 
12 months. The primary outcome of the trial is 6-month 
infant mortality (figure 2). Enrolment commenced in 
April 2019 and is expected to last until mid-2022.
objective and hypothesis
The objective of this study is to establish the safety and 
efficacy of administration of a single dose of oral azith-
romycin to neonates aged 8–27 days for the preven-
tion of infant mortality. We hypothesise that neonates 
randomised to azithromycin will have significantly lower 
all-cause mortality by 6 months of age compared with 
those randomised to placebo.
Study oversight
An independent Data and Safety Monitoring Committee 
(DSMC) oversees data collection and patient safety in 
this study. The DSMC contains members with expertise 
in paediatrics, infectious disease, biostatistics, bioethics 
and mass azithromycin distribution. The DSMC meets 
annually in a face-to-face meeting, including once prior 
to commencement of the study. Quarterly phone meet-
ings during the implementation of the trial take place 
to monitor progress and review safety data. In addition 
to the DSMC, a trial steering committee headquartered 
in Burkina Faso annually reviews the progress of the 
meeting. The steering committee meets annually to 
review trial progress and consists of key stakeholders in 
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Figure 2 SPIRIT schedule of enrolment, interventions and assessments.
policy, child health and research in Burkina Faso. Serious 
adverse events are reviewed by two medical monitors, one 
based in Burkina Faso and one in the USA.
Setting
This study is taking place in nine regions throughout 
Burkina Faso. All study sites are within a 4-hour drive of 
a facility with capability of performing pyloromyotomy 
(Centre Hospitalier Universitaire Pédiatrique Charles de 
Gaulle in Ouagadougou or Centre Hospitalier Univer-
sitaire Souro Sanou in Bobo Dioulasso). Study sites are 
situated in peri-urban (eg, outside of Ouagadougou) or 
rural areas. Pregnancies, births and newborns are identi-
fied and enrolled at a Centre de Santé et de Promotion Sociale 
(CSPS) in the study area. CSPSs are government nurse-led 
primary care facilities that offer preventive and curative 
care to catchment areas covering several rural villages.11 
Study headquarters are at the Centre de Recherche en 
Santé de Nouna in Nouna, northwestern Burkina Faso. 
All study personnel underwent didactic and hands-on 
training in good clinical practice, trial conduct and trial 
procedures. Study supervisors and investigators regularly 
review study data and conduct site visits to ensure adher-
ence to the trial protocol.
Recruitment
Newborns are recruited through several mechanisms, 
including identification of pregnant women in their third 
trimester, facility-based births, key informant or commu-
nity health worker systems in study areas, and through 
vaccination days. Pregnant women are informed about 
the study and asked to contact study staff after delivery if 
they are interested in their child participating in the trial. 
Women who give birth in facilities participating in the 
study are approached prior to discharge and are asked to 
return with their infant in 1–2 weeks for eligibility assess-
ment and enrolment. Verbal consent is obtained from 
pregnant women and women who have recently delivered 
to collect contact information, and to follow their preg-
nancy and contact them when the child is in the eligible 
window for enrolment if they are interested in their child 
participating in the study. Caregivers and newborns are 
also referred to the study by community health workers 
and key informants who work in the communities in the 
catchment areas for participating study clinics. Finally, 
women who return to health facilities with their infants for 
vaccination during the neonatal period are approached 
about the study if their child is in the eligible age range. 
In this setting, the BCG vaccination is typically given in 
the weeks following birth on a specified ‘BCG vaccination 
day’, and caregivers attending vaccination days are thus 
informed about the study. Caregivers of all children in 
the eligible age range are informed about the study.
Inclusion and exclusion criteria
Newborns are eligible to be enrolled if they are from 8 to 
27 days of age, weigh at least 2500 g at the time of enrol-
ment, have no known allergy to azalides, no neonatal jaun-
dice potentially indicating hepatic failure and are able to 
feed orally. Children who are too young or too small at 
initial evaluation can return for a second evaluation for 
inclusion in the trial as long as they are in the study’s enrol-
ment age range. While lower weight (which may be indica-
tive of younger gestational age, low birth weight or failure 
to thrive) children may benefit from the azithromycin 
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intervention, they are excluded from the trial due to mixed 
evidence of the role of birth weight and gestational age on 
risk of IHPS, some of which indicates that smaller babies 
are at increased risk of IHPS.12 In addition, the family of the 
newborn must intend to stay in the study area for at least 
6 months to minimise loss to follow-up and appropriate 
consent must be obtained from the caregiver.
Enrolment and baseline survey
After screening and prior to formal enrolment, written 
informed consent is obtained from the caregiver of all 
participants. Participants are then enrolled into the study 
and assigned a study identification number. The baseline 
assessment includes anthropometry (weight, length and 
mid-upper arm circumference measurement), recording 
of the child’s birth weight (obtained from the child’s health 
card), timing of initiation of breastfeeding and pregnancy 
type (singleton or multiple).
RAndoMISATIon
Children are randomised in a 1:1 fashion to a single 
dose of azithromycin or placebo. The randomisation list 
was generated by TCP and WWG in R V.3.3. Treatment 
letters that correspond to azithromycin or placebo were 
randomly assigned to study identification numbers. Chil-
dren are assigned via the study’s mobile application to a 
study identification number and thus a randomisation 
letter. To prevent accidental unmasking, a total of eight 
letters are used in the study, with four referring to azith-
romycin and four referring to placebo. Treatment bottles 
are labelled with study-specific labels that are identical in 
appearance with the exception of the treatment letter to 
facilitate masking.
Treatment and masking
Treatment is provided as a single, oral, directly observed 
dose of azithromycin (approximately 20 mg/kg, weight-
based dosing) or matching placebo. Azithromycin for 
oral suspension is provided in bottles containing azith-
romycin dehydrate powder equivalent to 1200 mg per 
bottle. The placebo oral suspension is identical to the 
azithromycin with the exception of the active ingredient 
to achieve masking. After children are weighed as part 
of the baseline anthropometric assessment, the tablet 
will automatically calculate the dosage of treatment. All 
study medications, including azithromycin and matching 
placebo, are donated by Pfizer.
Allocation concealment
Allocation concealment is achieved via masking and the 
electronic tablet. With a fully masked trial, study staff, 
investigators and participants are not aware of which 
assignment they will be given or have received. Further-
more, study staff are not aware of the randomisation 
letters that will be assigned to the next participant until 
that participant has undergone screening, informed 
consent, baseline assessment and randomisation. After 
the baseline visit is complete, the tablet displays the treat-
ment letters corresponding to the medication bottle with 
which the child will be treated. Viewing treatment letters 
prior to completion of the baseline form is not possible 
on the tablet, thus achieving allocation concealment.
Follow-up
All participants complete follow-up visits weekly for 3 
weeks after treatment and then at 3, 6 and 12 months 
of age. The weekly adverse event follow-up visits and the 
3-month and 12-month visits occur via phone call or home 
visit. The 6-month visit is an in-person visit conducted at 
the CSPS. To minimise loss to follow-up, several forms of 
contact information are obtained for each participant 
as well as their location of residence. Community health 
workers and key informants help facilitate follow-up visits, 
and home visits are conducted in case if participants 
are not contactable. For the primary outcome, a child’s 
vital status must be known to be considered not to lost 
follow-up (eg, the child is known to be alive at 6 months 
of age or known to have died at or before the 6-month 
visit). Information regarding whether the child was alive, 
died, had moved or their status was unknown is recorded 
at each time point.
Primary outcome measurement
The primary outcome is all-cause mortality determined at 
the 6-month study visit. Vital status is measured via inter-
view with the caregiver or head of household. Children 
who are living are evaluated in person at the CSPS or via 
home visit. Vital status is recorded in the study’s mobile 
application via tablet.
Secondary outcome measurements
12-month mortality. Vital status is measured via caregiver 
interview determined at 12 months of age. The 12-month 
study visit is conducted via phone call or in-person visit.
Neonatal mortality. As a prespecified secondary outcome, 
we will assess neonatal mortality (mortality prior to 28 
days of age) by study arm. Vital status will be measured in 
all children at each weekly follow-up visit for 3 weeks, and 
as such 28-day mortality will be measured in all children 
regardless of age of enrolment. Although we do not antic-
ipate that this secondary analysis will be fully powered, it 
is prespecified to assess if azithromycin dosing during the 
neonatal period has a large effect on neonatal mortality.
Hospitalisation. At each study visit, caregivers are asked 
if they had sought medical care for their child since they 
last spoke with the study team, and if so if their child had 
stayed overnight in a healthcare facility.
Anthropometric outcomes. At the 6-month study visit, 
anthropometric measurements including weight, length 
and mid-upper arm circumference are collected from all 
children. Weight gain from baseline in g/kg/day will be 
calculated to estimate weight gain velocity by study arm. 
Weight gain velocity in g/kg/day is a commonly used 
metric for weight gain, nutritional status over time and 
identification of growth deficits in newborns.13 14 Length 
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gain in mm/day will be calculated by study arm. Weight-
for-height Z-score (to measure wasting), height-for-age 
Z-score (to measure stunting) and weight-for-age Z-score 
(to measure underweight) will be calculated according to 
2006 WHO standards.15
Cause-specific mortality. A verbal autopsy interview will 
be undertaken with the caregiver of all children who 
die during the course of the study using the 2014 WHO 
verbal autopsy instrument or the neonatal verbal autopsy 
instrument if the death occurs before 4 weeks of age. 
Cause of death data will be analysed using the InterVA 
algorithm.16 17
Adverse events
The primary adverse event under surveillance is IHPS. 
Active surveillance for IHPS and other adverse events 
occurs via weekly screening of all enrolled children for 3 
weeks after treatment and at 3 months of age. Although 
evidence of timing of potentially macrolide-related IHPS 
is limited, previous studies have documented that pyloro-
myotomy was performed 2–4 weeks following exposure,4 
with symptoms developing prior to surgical correction. 
IHPS development is rare in children older than 6 weeks 
of age and is not expected to occur after 3 months of 
age.4 18 In addition, during the informed consent process 
the caregiver of all enrolled children is informed of the 
signs and symptoms of IHPS and asked to contact study 
staff should the child exhibit abnormal vomiting. All care-
givers are given a fact sheet with information about IHPS 
and its signs and symptoms. Children are enrolled in 
facilities where they would seek care if necessary, and all 
healthcare personnel in the facilities are aware of study 
activities. If a child enrolled in the study is brought to 
the facility, study staff are informed. If active or passive 
surveillance identifies a child with projectile or progres-
sive vomiting that occurs consistently after eating (ie, 
the child is unable to eat anything without vomiting), 
the child will be referred to the district hospital for eval-
uation of clinical symptoms and possible referral to the 
regional or national hospital for an ultrasound. Any child 
with projectile vomiting is followed until resolution. If the 
ultrasound indicates that the pylorus is hypertrophied per 
Burkinabé national guidelines (>4 mm for pyloric muscle 
thickness or >15 mm for pyloric length) or the measure-
ments are within normal limits but no food can pass per 
dynamic ultrasound, the child will be transferred to a 
national hospital for further evaluation, diagnosis and 
pyloromyotomy if IHPS is diagnosed. Children diagnosed 
with IHPS will be followed at 1 week and 4 weeks after 
surgery to ascertain surgical outcomes and then followed 
according to the study schedule.
In addition to screening for vomiting and IHPS, care-
givers are interviewed weekly for 3 weeks following treat-
ment for adverse events including rash, diarrhoea and 
fever. Caregivers are asked if they sought medical care for 
their child or if the child was hospitalised since the last 
visit by the study team and if so the indication for seeking 
treatment or hospitalisation. Finally, verbal autopsy is 
performed for all deaths to ascertain cause of death. The 
study’s DSMC reviewed and approved the adverse event 
monitoring plan prior to the start of recruitment and 
reviews all reports of IHPS in real time. Our adverse event 
monitoring protocol could be modified per DSMC recom-
mendation if, for example, IHPS was more common than 
anticipated. Although the DSMC reviews each IHPS case 
in real time in a masked fashion and study data in aggre-
gate quarterly, they may request IHPS or other safety 
data by arm if there are concerns related to safety. Each 
suspected case of IHPS is reviewed by two medical moni-
tors and all suspected cases are followed until resolution.
Interim analysis
One prespecified interim analysis for the primary outcome 
is planned when full data are available for one-third of 
the enrolments or after one full year of enrolment (eg, 6 
months after the last individual), whichever comes first. 
A p value of <0.001 is the prespecified stopping rule for 
efficacy for this interim analysis. Thus the final analysis 
will be conducted at an alpha of 0.049.
Statistical analysis
The primary analysis will be conducted as a binomial 
regression model with a complementary log-log link, 
with inferences based on a Monte Carlo permutation test 
based on the randomisation unit. The complementary 
log-log link allows for estimation of the relative hazard 
and can account for differing follow-up time. As a prespec-
ified subgroup analysis, we will assess effects of age at time 
of treatment in days using a binomial regression model, 
complementary log-log link and an interaction for treat-
ment arm by age. All statistical tests for efficacy will be 
two-sided. A p value of <0.05 will be considered statisti-
cally significant.
Sample size considerations
Assuming a mortality probability of 35 per 1000 and loss 
to follow-up of 10%, a sample size of 10 856 per arm (21 
712 total) would yield approximately 80% power to detect 
a 20% decrease in mortality in children randomised to 
azithromycin compared with placebo.
data management
Data are collected via smartphone in the field using 
Survey Solutions (World Bank Group, Washington, DC, 
USA), a cloud-based platform for electronic data collec-
tion. Smartphones are synced in the field to a cloud-based 
server.
Patient and public involvement
Members of the community, including key informants in 
the study communities, are involved in identification of 
births, recruitment of children and facilitating follow-up 
visits. Results will be disseminated in collaboration with 
community leadership in study areas. Patients and the 
public were not involved in the design or planning of the 
study.
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Ethics and dissemination
Written informed consent is obtained from the caregiver 
of each enrolled child (online supplementary file l). Effi-
cacy and safety results of this study will be disseminated to 
community, policy and scientific stakeholders, including 
the Ministry of Health in Burkina Faso, the WHO and 
relevant non-governmental organisations that implement 
child health policies. Results will be shared with the scien-
tific community via publication in peer-reviewed journals 
and presentation at international conferences.
dISCuSSIon
Although biannual mass azithromycin distribution has 
been shown to reduce all-cause child mortality in chil-
dren aged 1–59 months,12 this strategy may not reach 
the youngest children who may benefit the most. With 
biannual community distributions, children would first 
be reached any time between the age of 1 and 7 months 
or on average at approximately 4 months of age. Several 
strategies exist for reliably reaching younger children. For 
example, quarterly mass treatment would reach children 
at a younger age on average. Targeted treatment of young 
children is a strategy that may integrate well with existing 
health systems and can allow for reliably treated children 
at specific ages. In Burkina Faso, healthcare for children 
under five is free of charge, and as a result healthcare 
coverage for children is high. For example, vaccination 
coverage reportedly exceeded 80% in 2014 in Nouna.19 
If shown to be both efficacious and safe, targeting treat-
ment to the youngest, highest-risk children could be 
considered via integration with existing well-child visits in 
the health system.
IHPS is a rare but serious condition with approximately 
2 cases per 1000 infants in the USA.4 Surgical treatment 
is required. However, in many regions of sub-Saharan 
Africa, infant mortality rates far exceed the risk of IHPS.20 
Prevention of a portion of infant mortality in the highest 
risk areas may therefore offer substantial benefits for 
populations. However, the associated risks of IHPS as well 
as the efficacy must be well understood before any such 
policy could be put into place. In this study, a compre-
hensive screening and referral protocol are in place to 
identify any cases of IHPS that arise during the course 
of the study. We expect that the results of this study will 
provide evidence of the risks and benefits of treatment 
of neonates with azithromycin for prevention of child 
mortality.
To date, existing evidence for the relationship between 
macrolide use and development of IHPS has been limited 
to observational studies or small randomised trials of azith-
romycin for prevention of bronchopulmonary dysplasia 
in low birth weight infants.21–23 In a large retrospective 
cohort study in the USA, among 4875 infants up to 90 
days of life, 8 cases of IHPS occurred, with a higher risk of 
IHPS among children receiving erythromycin or azithro-
mycin compared with cephalexin.4 This risk appeared to 
be higher in children receiving erythromycin compared 
with azithromycin, and among children under 14 days of 
age compared with older children. Observational studies 
are limited by confounding by indication, which could 
occur if children with conditions necessitating a macro-
lide have different conditions or are otherwise substan-
tively different from those who receive another antibiotic 
class or no antibiotics. Existing randomised controlled 
trials have been small (total n=263 infants randomised), 
and no cases of IHPS have been detected. Relatively little 
evidence of the epidemiology of IHPS in sub-Saharan 
Africa exists,24–26 although some have hypothesised that 
IHPS is less common in developing country settings 
compared with high-income settings due to different 
feeding and medication practices.26–28 The results of this 
study are expected to provide comprehensive, rigorous 
evidence of the relationship between azithromycin use 
and IHPS in neonates, as well as important data on the 
epidemiology of IHPS in rural West Africa.
Several limitations must be considered in this study. 
This study was designed under the principle of a large 
simple trial, due to the large sample size required to be 
adequately powered for a rare outcome.29 30 However, 
careful attention must be paid to each individual in the 
trial due to the risk of IHPS. The focus is on measuring 
the most important outcomes (mortality and IHPS), and 
thus measurement of additional secondary outcomes 
is limited. For example, the potential for antimicrobial 
resistance is an important consideration with the use of 
azithromycin for child health.31 32 Parallel individual and 
cluster randomised trials are currently evaluating the 
effect of azithromycin on selection for macrolide resis-
tance in neonates and older children ( ClinicalTrials. gov 
NCT03676751 and NCT03676764). Given the absence of 
IHPS data from rural sub-Saharan Africa and the expected 
rarity of the event, the study may be underpowered to 
detect differences in IHPS between study arms. Stopping 
rules for safety are based not only on statistical signifi-
cance, but decisions will be made in conjunction with 
the DSMC based on case reports arising from the study. 
The results of this study are expected to be generalisable 
to neonates in similar West African settings, but results 
may not be generalisable outside of rural West Africa, 
where infectious aetiology leading to infant mortality 
may be different. Results may also not be generalisable 
to low-weight neonates, as they were excluded from the 
trial. We anticipate that the study will provide the largest 
sample to date providing evidence of the epidemiology 
of IHPS in West Africa, as well as the largest trial to date 
evaluating azithromycin for IHPS.
ConCluSIonS
The results of this study are expected to inform policy 
related to the use of azithromycin for prevention of child 
mortality by specifically evaluating the role of targeting 
doses during early infancy when the risk of infectious 
mortality is highest. This work is anticipated to build on 
the evidence base arising from the MORDOR study, which 
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demonstrated that biannual mass treatment significantly 
reduces all-cause child mortality in children aged 1–59 
months. If proven to be safe and effective, the evidence 
arising from this study could be used to develop policies 
related to administration of azithromycin during the 
neonatal period.
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